Your browser doesn't support javascript.
loading
Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al.
Sun, L; Brazão, C; Mancha, D; Soares-de-Almeida, L; Filipe, P.
Affiliation
  • Sun L; Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
  • Brazão C; Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
  • Mancha D; Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
  • Soares-de-Almeida L; Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
  • Filipe P; Dermatology Universitary Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
J Eur Acad Dermatol Venereol ; 37(5): e578-e580, 2023 05.
Article in En | MEDLINE | ID: mdl-36681888
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pemphigoid, Bullous / Antibodies, Monoclonal, Humanized / COVID-19 Vaccines / COVID-19 Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pemphigoid, Bullous / Antibodies, Monoclonal, Humanized / COVID-19 Vaccines / COVID-19 Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2023 Document type: Article Affiliation country: Country of publication: